Advances in Cancer Vaccines as Promising Immuno-Therapeutics
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".
Deadline for manuscript submissions: 31 July 2024 | Viewed by 2966
Special Issue Editor
Special Issue Information
Dear Colleagues,
Cancer is a disease accounting for a large number of deaths year by year worldwide. In 2020 alone, more than 19.3 million (19,300,000) new cancer cases were diagnosed, resulting in about 10 million deaths. The continuous emerging incidences of cancer worldwide have warranted the need for the development of potent pharmaceuticals for treating different cancers.
In the past decade, immunotherapy has made a huge impact on the treatment of various types of cancer, providing durable remissions and extended survival in a subset of patients. Currently there are several types of immunotherapies, such as monoclonal antibodies, checkpoint inhibitors, vaccines, CAR-T cell therapy, etc. Cancer vaccines are considered a promising therapeutic strategy in the immunotherapy of solid tumors, which stimulates anti-tumor immunity with tumor antigens. Perfect cancer vaccines could overcome the immune suppression in tumors and induce both humoral immunity and cellular immunity. This Special Issue aims to understand the advances in cancer vaccines when it comes to treating different tumors.
We are pleased to invite you to submit original research, reviews and perspective articles that cover, but are not limited to, the following subtopics:
- Advances in the identification of neo-antigens for cancer vaccines;
- Advances in the adjuvants for cancer vaccines;
- Advances in delivering systems for cancer vaccines;
- Advances in cancer vaccine platforms;
- The efficacy of cancer vaccines alone or in combination with other immunotherapy approaches in pre-clinical models.
I look forward to receiving your contributions.
Dr. Ling Ni
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer vaccines
- tumor antigens
- adjuvants
- delivery system
- vaccine platform
